Jun 1, 2023 · Regulatory information

Cantargia announces updates to the management team

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that Dr. David Liberg, member of Cantargia’s management team, has been promoted to Chief Scientific Officer (CSO). Additionally, Patrik Renblad will formally take on the role as Chief Financial Officer (CFO) starting June 15, 2023.

Dr. Liberg joined Cantargia in 2015 and has since been part of Cantargia’s management team and held the role of VP Research. He has over 25 years of experience in immunology and tumor biology research with a background from Active Biotech and Imperial College in London. Dr. Liberg has played a key role in advancing the preclinical and translational development of Cantargia’s lead asset nadunolimab (CAN04), as well as its second development project CAN10.

“I am truly honored to accept the position of Chief Scientific Officer and look forward to working together with the many talented people in our organization to further advance Cantargia’s project portfolio with the aim to provide benefit to patients with cancer and inflammatory disorders,” said David Liberg, CSO of Cantargia.

Cantargia previously announced that Patrik Renblad will replace current CFO Bengt Jöndell no later than August 1, 2023. Mr. Renblad will assume the position as CFO and join Cantargia’s management team from June 15, 2023.

“Cantargia has made significant progress during 2023 and the changes to the management team puts the company in a strong position to continue to deliver on these results,” said Göran Forsberg, CEO of Cantargia.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

About nadunolimab (CAN04)
The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR evaluates nadunolimab in combination with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) or NSCLC (platinum-based chemotherapies) (NCT03267316). Positive interim data show durable responses for the combination therapy in 73 PDAC patients, resulting in median iPFS of 7.2 months and median OS of 12.9 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 30 NSCLC patients with median PFS of 7.0 months and a response rate of 53%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase Ib/II trial TRIFOUR (NCT05181462) also shows signs of promising efficacy in TNBC with a 50% response rate for nadunolimab combined with carboplatin/gemcitabine. Nadunolimab is also investigated with chemotherapy in the clinical trials CAPAFOUR (NCT04990037) and CESTAFOUR (NCT05116891), and with the checkpoint inhibitor pembrolizumab in the CIRIFOUR trial (NCT04452214).